STK11 and non-small cell lung carcinoma: Furthermore, a prior study with the WEE1 inhibitor adavosertib (AstraZeneca) identified preclinical efficacy in STK11-deficient NSCLC (58), providing additional rationale for combining azenosertib and KRASG12C inhibition in tumors with this genotype.